Ronald Hurst, M.D.
Ronald Hurst, MD, FACS is a board-certified surgeon as part of the Division of Surgical Oncology at The Angeles Clinic and Research Institute. Dr. Hurst was born and raised in South Central Los Angeles. He completed his General Surgical training at Martin Luther King/Drew Medical Center where he subsequently was selected as Executive Chief Resident, following which he completed surgical oncology training under Dr. Steven A. Rosenberg at the National Institutes of Health, National Cancer Institute in Bethesda Maryland. During his surgical oncology fellowship, his research efforts were concentrated in tumor immunology analyzing TCRbV usage in response to tumor vaccines for melanoma using competitive PCR to quantitate the frequency of TCR subfamilies in PBMC.
Dr. Hurst joined the department of surgery at the King/Drew Medical Center from 2000-2003 as founding chief of the new surgical oncology service. During this period he worked to streamline the breast clinic to provide care to 80-100 patients a week and to establish a surgical oncology clinic, a combined surgical oncology/pathology weekly conference, and instituted a stereotactic breast biopsy program and a sentinel lymph node biopsy program for breast cancer and melanoma.
In 2001, Dr. Hurst joined the staff at Centinela Hospital, Cedars-Sinai Marina del Rey Hospital, Southern California Hospital at Culver City, and Little Company of Mary Hospital as a surgical oncologist specializing in breast, colorectal, thyroid, and parathyroid surgery and sarcoma cancers as well as general surgery. He is a skillfully trained robotic surgeon with extensive experience in robotic gastrointestinal surgeries, ventral and inguinal hernias, and gallbladder disease. While at Centinela Hospital he developed and instituted the robotic program and served as the Director of the Robotic Surgery Program. Currently, he is Chairman of the Department of Surgery at Cedar-Sinai Marina del Rey.
Dr. Hurst has received numerous awards and since 2003 has been honored with the recognition of being one of America’s Top Surgeons consecutively. Dr. Hurst has always had a passion for educating underrepresented communities on cancer awareness and prevention. Dr. Hurst partnered with the California Oncology Research Institute and established an extensive community outreach program offering free lectures on breast, colon, and GYN malignancies as well as free mammograms to inner-city communities from 2011-2018. His goal was to allow people of color to have access to state-of-the-art cancer care without leaving their community.
In addition to Dr. Hurst’s commitment to medicine, he honorably served his country in the United States Army Reserve for 20 years and retired with the rank of Lieutenant Colonel. He served on two deployments, one for Operation Iraqi Freedom 2003 and the other for Operation Enduring Freedom (Afghanistan) in 2011. He was honorably discharged in 2012.
His office will be at the Wilshire location where he will see patients as well as in the Marina. He has privileges at Cedars-Sinai Marina del Rey hospital and Cedars-Sinai Medical Center. Dr. Hurst can be reached at the following number, 310-582-7998, and his physician practice coordinator for patient scheduling is Jackie Soto.
Procedures Dr. Ronald Hurst Performs at Cedars-Sinai Marina del Rey Hospital
- Blue Cross / Blue Shield
- Coventry Health Care
- United Healthcare
Education & Training
Creighton University School Of Medicine
Martin Luther King-Drew Harbor Medical Center, Los Angeles, CA
Martin Luther King/Drew UCLA Med Center
National Institute Hlth/Natl Cancer Insti
Honors & Awards
Memberships & Affiliations
Publications & Media
Laparoscopic Continuous Hyperthermic Peritoneal Perfusion
Eugene Change, M.D., H. Richard Alexander, M.D., Steven K. Libutti, M.D., Ronald Hurst, M.D., Suoping Zhai, Ph.D., William D. Figg, M.D., David L. Bartlett, M.D.: “Laparoscopic Continuous Hyperthermic Peritoneal Perfusion”. Journal of the American College of Surgeons. Aug 2001;193(2):225-9.
Brain Metastasis After Immunotherapy in Patients with Metastatic Melanoma or Renal Cell Cancer: Is Craniotomy Indicated?
R. Hurst, M.D., D. White, J Heiss, M.D. D. Lee, M.D. S. A. Rosenberg, M.D. D. Schwartzentruber, M.D.: “Brain Metastasis After Immunotherapy in Patients with Metastatic Melanoma or Renal Cell Cancer: Is Craniotomy Indicated?” Journal of Immunotherapy vol 22 No.4, 1999.
Patterns of Relapse and Response to Retreatment in Patients with Metastatic Melanoma or Renal Cell Carcinoma who Responded to Interleukin-2 based Immunotherapy
D. S. Lee, M.D., D. White, R. Hurst. M.D., S.A. Rosenberg, M.D., J. Yang, M.D.: “Patterns of Relapse and Response to Retreatment in Patients with Metastatic Melanoma or Renal Cell Carcinoma who Responded to Interleukin-2 based Immunotherapy”. Journal of The American College of Surgeons.
Prospective Randomized Evaluation of the Prophylactic Use of Low-dose Dopamine in Cancer Patients Receiving Interleukin-2
J. N. Cormier, M.D., R. Hurst, M.D., J. Vasselli, M. D., D. Lee, M.D., C. Kim, M.D., M. McKee, M.D., D. Venzon, D. White, F. Marincola, M.D., S. Rosenberg, M.D.: “Prospective Randomized Evaluation of the Prophylactic Use of Low-dose Dopamine in Cancer Patients Receiving Interleukin-2”. Journal of Immunology March, 1997.
Rectal Carcinoma: Are We Making A Difference?
R. Hurst, M.D., G. D. Wilmoth, M.D., M. Stamos, M.D.: “Rectal Carcinoma: Are We Making A Difference?” Am Surg-1996 Oct; 62(10): 806-10.